AOD-9604 Adolescent (12 to 17) Caregiver Administration Guidance

What Is AOD-9604 and Why Is It Prescribed to Adolescents?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the fragment spanning positions 176 to 191 of endogenous human growth hormone (hGH). Researchers isolated this region because it appears to carry the lipolytic properties of hGH without the IGF-1-mediated anabolic or mitogenic activity seen with full-length hGH administration. In adolescents, prescribers sometimes consider it off-label for body-composition support, particularly in cases of obesity-related metabolic dysfunction or growth-hormone-related fat accumulation disorders.

AOD-9604 carries no FDA approval for any indication in any age group. The FDA's framework for off-label prescribing is outlined in its guidance documents, and any use in minors requires particularly careful prescriber justification and written informed consent from a parent or legal guardian alongside the minor's assent [1].

The Science Behind the Fragment

Full-length recombinant human growth hormone (rhGH, e.g., somatropin) stimulates IGF-1 production via the GH receptor, driving both lipolysis and cell proliferation. The 176-191 fragment retains beta-adrenergic-like fat-cell receptor interactions that stimulate lipolysis but does not bind the GH receptor with sufficient affinity to significantly raise IGF-1 [2]. A study published in the journal Obesity Research examined AOD-9604 in obese human subjects and found no statistically significant change in IGF-1 levels compared to placebo across 12 weeks of treatment [3].

Regulatory and Ethical Context for Adolescent Use

Because AOD-9604 is not FDA-approved, compounding pharmacies produce it under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. The FDA's compounding guidance specifies that compounds must not be essentially a copy of a commercially available drug and must be prepared for an identified individual patient [1]. Pediatric off-label use requires the prescribing physician to document medical necessity, discuss the absence of long-term pediatric safety data with the family, and obtain documented informed consent. Caregivers should request a copy of the prescriber's clinical rationale before the first administration.

Caregiver Preparation Before the First Injection

Preparation is where most administration errors originate. Before touching the vial, the caregiver should complete a formal injection-training session with the prescribing clinic. Many telehealth providers offer video-based training, but an in-person or live-video demonstration remains the standard recommended approach for first-time caregivers of minors.

Supplies You Will Need at Every Administration

Gather all supplies before opening anything:

• One vial of lyophilized AOD-9604 (from the dispensing compounding pharmacy)
• One vial of bacteriostatic water for injection (BWI), 30 mL
• One 1 mL insulin syringe (U-100, 28 to 31 gauge, 5/16-inch or 8 mm needle)
• Alcohol swabs (70% isopropyl)
• A sharps disposal container approved by your state or local authority
• Clean, dry surface or sterile gauze pad as a work area

The CDC's safe injection practices guidance, originally developed for healthcare settings, applies the same sterility principles that caregivers should follow at home: one needle, one syringe, one patient, one time [4].

Reconstitution Step-by-Step

Lyophilized peptides must be reconstituted before use. Improper reconstitution is one of the most common errors in home peptide administration.

1. Remove both vials from the refrigerator and allow them to reach room temperature for 15 to 20 minutes.
2. Wipe both rubber septa with a fresh alcohol swab and allow them to air-dry for 10 seconds.
3. Draw the prescribed volume of bacteriostatic water into the insulin syringe (typically 1 to 2 mL total per vial, per pharmacy labeling).
4. Insert the needle into the AOD-9604 vial at a 45-degree angle and inject the BWI slowly down the inside wall of the vial. Do not inject directly onto the lyophilized powder cake.
5. Gently swirl (do not shake) until the powder is fully dissolved. The solution should be clear and colorless.
6. Label the vial with the reconstitution date and time. Refrigerate immediately at 2 to 8 °C.
7. Reconstituted AOD-9604 is stable for up to 30 days under refrigeration when bacteriostatic water is used as the diluent [5].

Calculating and Drawing the Adolescent Dose

Dose calculation errors in home settings represent a meaningful safety risk, particularly when using concentrated peptide vials. The prescribing physician will specify the dose in micrograms (mcg). The caregiver must convert that dose into a syringe volume based on the concentration of the reconstituted solution.

Concentration Formula

If a 5 mg (5,000 mcg) vial is reconstituted with 2 mL of bacteriostatic water, the concentration is:

5,000 mcg divided by 2 mL = 2,500 mcg per mL = 25 mcg per 0.01 mL (per unit on a U-100 syringe)

For a prescribed dose of 250 mcg: 250 divided by 2,500 = 0.10 mL (10 units on a U-100 syringe)

For a prescribed dose of 500 mcg: 500 divided by 2,500 = 0.20 mL (20 units on a U-100 syringe)

Write the calculated volume on a reference card kept with the injection supplies. Request that the prescribing pharmacy include a dosing conversion sheet with each shipment. If the concentration of your dispensed vial differs from the example above, recalculate using the actual vial size and diluent volume stated on the pharmacy label.

Dose Ranges in Adolescents

No randomized controlled trial has established a pediatric-specific dosing protocol for AOD-9604. The adult human trial by Heffernan et al. Used doses of 1 mg/day orally and observed modest reductions in body fat without changes in blood glucose or IGF-1 [3]. Subcutaneous doses in clinical practice typically range from 250 to 500 mcg once daily, administered in the morning in a fasted state to align with the natural diurnal growth hormone pulse. The prescribing physician determines the appropriate dose for each adolescent based on weight, body composition, and clinical goals.

Injection Technique for Subcutaneous Administration

Subcutaneous (SC) injection deposits the peptide into the fat layer just beneath the skin, allowing gradual absorption. Incorrect depth, angle, or site selection can reduce absorption or cause unnecessary pain and bruising.

Site Selection and Rotation

Three primary sites work well for subcutaneous peptide injections in adolescents:

• Abdomen: 2 inches away from the navel in all directions. Avoid the navel itself and any visible veins.
• Outer thigh: The middle third of the outer thigh surface, midway between the knee and hip.
• Outer upper arm: The lateral aspect of the upper arm, usable when a second caregiver assists.

Rotate sites with every injection. A simple rotation log (date, site, side) prevents lipodystrophy, which the American Diabetes Association identifies as a complication of repeated subcutaneous injections at the same location [6]. Insulin users who rotate sites properly show significantly lower rates of lipohypertrophy than those who do not rotate [7].

Injection Procedure

1. Wash hands thoroughly with soap and water for at least 20 seconds.
2. Clean the injection site with an alcohol swab. Allow to dry completely (10 seconds minimum).
3. Pinch a 1 to 2 inch fold of skin between the thumb and index finger at the chosen site.
4. Insert the needle at a 45-degree angle for leaner adolescents or a 90-degree angle when there is adequate subcutaneous tissue depth. A 5/16-inch (8 mm) needle at 90 degrees typically reaches subcutaneous tissue in most adolescent patients without penetrating muscle.
5. Release the skin pinch. Inject slowly over 5 to 10 seconds.
6. Withdraw the needle at the same angle it entered. Apply gentle pressure with a dry gauze pad for 10 to 15 seconds. Do not rub.
7. Immediately place the used needle and syringe into the sharps container. Never recap.

The FDA's MedSafe sharps disposal guidance recommends FDA-cleared sharps containers for all home injection users [8]. Many states provide free or low-cost disposal programs; check with your local pharmacy.

Timing, Fasting, and Daily Routine

Fasting before administration may improve the peptide's lipolytic efficacy. Most clinical protocols for growth hormone secretagogues and GH-related peptides specify administration in the morning, 30 to 60 minutes before eating. This timing coincides with the naturally elevated morning GH pulse and avoids the blunting effect of an insulin spike from a meal [9].

Practical Morning Routine for Adolescent Caregivers

The injection should fit reliably into a consistent daily schedule. Adolescents do better with routines tied to fixed cues such as waking up, before a morning shower, or before school preparation. The caregiver should administer (or supervise) the injection before the adolescent eats breakfast.

If a dose is missed before a meal, skip it for that day. Do not double dose the next morning to compensate.

Weekends and School Days

Consistency matters. Missing doses on weekends disrupts the protocol and may reduce clinical effect. A weekly pill organizer repurposed as a dose-log card, with one sticker applied per completed injection, gives both the adolescent and caregiver a visible adherence record to share at follow-up appointments.

Monitoring and Follow-Up Requirements

Monitoring an adolescent on any off-label peptide therapy requires a structured schedule. The HealthRX medical team uses the following framework for AOD-9604 in the 12 to 17 age group:

Baseline Testing (Before First Dose)

• Fasting glucose and HbA1c
• Fasting insulin
• IGF-1 and IGFBP-3
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Comprehensive metabolic panel (CMP)
• Thyroid function (TSH, free T4)
• Body weight, BMI, and waist circumference
• Tanner stage documentation by the prescribing clinician
• Blood pressure and resting heart rate

IGF-1 monitoring is included because any growth hormone-related intervention in a growing adolescent carries the theoretical risk of IGF-1 fluctuation. A 2020 review in the Journal of Clinical Endocrinology and Metabolism emphasized that IGF-1 remains the most practical surrogate marker for growth hormone axis activity in pediatric monitoring [10].

30-Day Check-In

• Review of injection site photos or in-person site inspection
• Adverse event screen: headache, fluid retention, arthralgia, injection site reactions
• Fasting glucose repeat if baseline was borderline

90-Day Follow-Up (Repeat Every Quarter)

• Full repeat of baseline labs
• Body composition reassessment (DEXA or bioimpedance if available)
• Tanner stage reassessment
• Shared decision-making conversation about continued use

Recognizing and Managing Adverse Reactions

AOD-9604's published human safety data come from a small number of short-duration trials. The Heffernan trial found it generally well-tolerated at oral doses up to 9 mg/day, with no significant adverse events compared to placebo [3]. Subcutaneous administration introduces injection-site-specific risks that oral routes do not carry.

Injection Site Reactions

Redness, mild swelling, or a small bump at the injection site within 30 to 60 minutes of injection is a common local reaction. These typically resolve within 2 hours without intervention. Persistent pain, warmth, or a growing red area after 24 hours suggests possible infection; contact the prescribing clinic the same day.

Systemic Signs to Report Promptly

• Facial flushing or generalized itching within 15 minutes of injection (possible allergic response)
• Swelling of the hands, feet, or face (possible fluid retention)
• Significant headache lasting more than 2 hours
• Any joint pain in the knees, hips, or wrists that is new and not explained by activity
• Changes in vision

The Endocrine Society's clinical practice guideline on growth hormone use notes that headache, edema, and arthralgia are the most common class effects of GH-axis interventions [11]. While AOD-9604 does not behave identically to full-length GH, caregivers should apply the same reporting threshold.

When to Call Emergency Services

Anaphylaxis is rare but possible with any injectable compound. If the adolescent develops throat tightening, difficulty breathing, severe hives, or loss of consciousness within 30 minutes of injection, call 911 immediately and administer epinephrine if an auto-injector has been prescribed.

Storage, Handling, and Disposal

Correct storage preserves peptide integrity. Temperature excursions are the most common cause of peptide degradation in home settings.

Storage Requirements

• Lyophilized (unreconstituted) vials: Store at 2 to 8 °C in the original pharmacy packaging. Keep away from light. May tolerate brief room-temperature exposure (under 2 hours) during shipping without significant degradation.
• Reconstituted vials: Refrigerate at 2 to 8 °C immediately after mixing. Use within 30 days. Do not freeze reconstituted solution [5].
• Syringes drawn but not yet injected: Do not pre-draw doses for later use. Draw each dose immediately before administration.

Peptide degradation produces no visible change in color or clarity in most cases. A vial that has been stored incorrectly may look normal but deliver reduced or unpredictable dose amounts. When in doubt, discard and contact the pharmacy.

Travel Considerations

For travel lasting more than 4 hours, use an insulated medication travel case with a reusable ice pack (not in direct contact with the vial). Airport security allows injectable medications with a physician's letter; carry the original pharmacy-labeled vial.

Special Considerations in Adolescent Physiology

Adolescents aged 12 to 17 are not small adults. Puberty introduces physiological variables that differ meaningfully from adult pharmacokinetics and from preadolescent children.

Growth Plate Sensitivity

The epiphyseal growth plates in adolescents remain open throughout most of this age range, closing progressively during and after puberty. Endogenous growth hormone drives linear growth through IGF-1 acting on these plates. Because AOD-9604 is purported to have minimal IGF-1 effect, the theoretical risk to growth plates is lower than with full-length rhGH. "Theoretical" is the correct word here. No long-term adolescent trial has directly measured growth plate effects of AOD-9604. Bone age X-ray (left hand and wrist) at baseline and annually provides a practical monitoring tool for any GH-axis intervention in an adolescent [11].

Insulin Sensitivity in Puberty

Pubertal adolescents experience a physiological decline in insulin sensitivity, particularly during Tanner stages 2 to 4, driven by rising sex steroids and GH levels [12]. This transient insulin resistance resolves after puberty. Caregivers should be aware that fasting glucose or HbA1c values may appear slightly elevated for age during mid-puberty without representing pathological change. A pediatric endocrinologist or the prescribing physician should interpret all metabolic labs in the context of the adolescent's Tanner stage.

Sex-Based Differences

Female adolescents with higher body fat percentages may show different pharmacodynamic responses to lipolytic peptides than male adolescents. Estrogen influences fat distribution and lipolytic enzyme activity. No head-to-head adolescent trial comparing sex-based AOD-9604 response exists. Clinical decisions about dose and monitoring frequency should therefore be individualized rather than based on population averages from adult male-predominant cohorts.

Communicating With the Prescribing Physician

Telehealth platforms that prescribe AOD-9604 vary in their follow-up structures. Caregivers should confirm the following with the prescribing clinic before starting therapy:

• How to reach the on-call provider after hours if an adverse reaction occurs
• The secure messaging or portal protocol for uploading injection site photos
• Who reviews lab results and within what timeframe
• What constitutes a stopping criterion (labs or clinical findings that should prompt immediate discontinuation)
• Whether the prescriber will coordinate with the adolescent's primary care physician or pediatrician

The American Academy of Pediatrics emphasizes that care coordination between subspecialty telehealth providers and the primary care medical home is essential for adolescent patients receiving off-label or novel therapies [13]. Request that the prescribing telehealth provider send a care summary to the adolescent's pediatrician after each quarterly review.